ID: ALA217494

Max Phase: Preclinical

Molecular Formula: C15H17N3O3S

Molecular Weight: 319.39

Molecule Type: Small molecule

Representations

Canonical SMILES:  O=C(CCCCSc1nc(-c2ccccc2)cc(=O)[nH]1)NO

Standard InChI:  InChI=1S/C15H17N3O3S/c19-13(18-21)8-4-5-9-22-15-16-12(10-14(20)17-15)11-6-2-1-3-7-11/h1-3,6-7,10,21H,4-5,8-9H2,(H,18,19)(H,16,17,20)

Standard InChI Key:  RZORLCCEOIZMPJ-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 319.39

Molecular Weight (Monoisotopic): 319.0991

AlogP: 2.20

#Rotatable Bonds: 7

Polar Surface Area: 95.08

Molecular Species: NEUTRAL

HBA: 5

HBD: 3

#RO5 Violations: 0

HBA (Lipinski): 6

HBD (Lipinski): 3

#RO5 Violations (Lipinski): 0

CX Acidic pKa: 7.67

CX Basic pKa: 0.48

CX LogP: 1.70

CX LogD: 1.53

Aromatic Rings: 2

Heavy Atoms: 22

QED Weighted: 0.24

Np Likeness Score: -1.28

References

1. Mai A, Massa S, Rotili D, Simeoni S, Ragno R, Botta G, Nebbioso A, Miceli M, Altucci L, Brosch G..  (2006)  Synthesis and biological properties of novel, uracil-containing histone deacetylase inhibitors.,  49  (20): [PMID:17004718] [10.1021/jm0605536]

2. Mai A, Rotili D, Massa S, Brosch G, Simonetti G, Passariello C, Palamara AT..  (2007)  Discovery of uracil-based histone deacetylase inhibitors able to reduce acquired antifungal resistance and trailing growth in Candida albicans.,  17  (5): [PMID:17196388] [10.1016/j.bmcl.2006.12.028]

3. Paris M, Porcelloni M, Binaschi M, Fattori D..  (2008)  Histone deacetylase inhibitors: from bench to clinic.,  51  (6): [PMID:18247554] [10.1021/jm7011408]

Source

Source(1):

• Scientific Literature